By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
XATMEP Drug Profile
Email this page to a colleague
Which patents cover Xatmep, and what generic alternatives are available?
Xatmep is a drug marketed by Azurity and is included in one NDA. There are four patents protecting this drug.
This drug has three patent family members in three countries.
The generic ingredient in XATMEP is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xatmep
A generic version of XATMEP was approved as methotrexate sodium by WEST-WARD PHARMS INT on September 16th, 1986.
Summary for XATMEP
| International Patents: | 3 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Patent Applications: | 4,333 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XATMEP |
| What excipients (inactive ingredients) are in XATMEP? | XATMEP excipients list |
| DailyMed Link: | XATMEP at DailyMed |
Pharmacology for XATMEP
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
US Patents and Regulatory Information for XATMEP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XATMEP
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United Kingdom | 201200192 | Get Started Free |
| Spain | 2726524 | Get Started Free |
| European Patent Office | 2614814 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
